Fabrication and Evaluation of Pluripotent Stem Cells Expressing in Human iPS Cells as In-vitro Model
Main Article Content
Abstract
Our latest report details the production of human induced pluripotent stem cells (iPSC) master cell banks (MCB) that are produced by a therapeutically compliant approach that starts with cord blood. The two iPSC clones created by this method were thoroughly characterised in this publication, utilising whole genome sequencing (WGS), microarray, and comparative genomic hybridization (aCGH) single nucleotide polymorphism (SNP) analysis. We compare these profiles with lines created by a similar procedure from different donors, a reporter subclone, and a suggested calibration material. We think it is likely that several clinical products will be made using iPSCs. Furthermore, given their immortal state, we anticipate that the lines utilised as input material will be used for many years or even decades at various sites. As a result, assay development will be crucial to tracking the condition of the cells and their drift within the culture. We propose that a thorough description of the cells' starting state, a comparison with some calibration data, and the creation of reporter sublcones will aid in identifying the most beneficial set of tests for keeping an eye on the cells and defining standards for eliminating a line.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Baghbaderani B. A., Tian X., Neo B. H. cGMP manufactured human induced pluripotent stem cells are available for Pre-clinical and clinical applications. Stem Cell Reports. 2015; 5(4):647–59.
Thomson J. A., Itskovitz-Eldor J., Shapiro S. S. Embryonic stem cell lines derived from human blastocysts. Science. 1998; 282(5391): 1145–7.
Takahashi K., Tanabe K., Ohnuki, M. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131(5): 861–72.
Tchieu J., Kuoy E., Chin M. H. Female human iPSCs retain an inactive X chromosome. Cell Stem Cell. 2010; 7(3): 329–42.
Hanna J. H., Saha K., & Jaenisch R. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell. 2010; 143(4): 508–25.
Guenther M. G., Frampton G. M., Soldner F. Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells. Cell Stem Cell. 2010; 7(2):249–57.
Bar-Nur O., Russ H. A., Efrat S. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell. 2011; 9(1): 17–23.
Liang G., & Zhang Y. Genetic and epigenetic variations in iPSCs: potential causes and implications for application. Cell Stem Cell. 2013; 13(2): 149–59.
Yamanaka S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell. 2010; 10(6): 678–84.
Cheng L., Hansen N. F., Zhao L. Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. Cell Stem Cell. 2012; 10(3):337–44.
http://www.ipscell.com/2015/07/takahashi_cea/.
Carpenter M. K., & Rao M. S. Concise review: making and using clinically compliant pluripotent stem cell lines. Stem Cells Translational Medicine. 2015; 4:381–388.
Mcallister T. N., Audley D., & L'heureux N. Autologous cell therapies: challenges in US FDA regulation. Regenerative Medicine. 2012; 7(6 Suppl): 94–7.
Baghbaderani B. A., Rao M. S., & Fellner T. Manufacturing human induced pluripotent stem cells for clinical applications. Bio Process International. 2015; 13(9s):10–21.
Zhou H., & Rao M. S. Can cord blood banks transform into induced pluripotent stem cell banks? Cytotherapy. 2015; 17(6): 756–64.
Turner M., Leslie S., Martin N. G. Toward the development of a global induced pluripotent stem cell library. Cell Stem Cell. 2013;13(4):382–4.
Chen G., Gulbranson D. R., Hou Z. Chemically defined conditions for human iPSC derivation and culture. Nature Methods. 2011; 8(5):424–9.
Dowey S. N., Huang X., Chou B. K. Generation of integration-free human induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector expression. Nature Protocols. 2012; 7(11):2013–21.
Zeng X., Chen J., Sanchez J. F. Stable expression of hrGFP by mouse embryonic stem cells: promoter activity in the undifferentiated state and during dopaminergic neural differentiation. Stem Cells. 2003; 21(6): 647–53.
Raczy C., Petrovski R., Saunders C. T. Isaac: ultrafast whole-genome secondary analysis on Illumina sequencing platforms. Bioinformatics. 2013; 29(16):2041–3.
Cingolani P., Platts A., Le Wang L. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly. 2012; 6(2): 80–92.
Lassmann T., Hayashizaki Y., & Daub C. O. SAM Stat: monitoring biases in next generation sequencing data. Bioinformatics. 2011; 27(1): 130–1.
Giollo M., Minervini G., Scalzotto M. BOOGIE: predicting blood groups from high throughput sequencing data. PloS One. 2015; 10(4): e0124579.
Nariai N., Kojima K., Saito S. HLA-VBSeq: accurate HLA typing at full resolution from whole-genome sequencing data. BMC Genomics. 2015; 16(Suppl 2), S7.
Ng, P. C., & Henikoff, S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Research. 2003; 31(13):3812–4.
Adzhubei I., Jordan D.M., Sunyaev S.R. Predicting functional effect of human missense mutations using PolyPhen-2. Current protocols in human genetics / editorial board, Jonathan L Haines [et al.].;Chapter 7:Unit7 20. 2013.
Liu X., Jian X., & Boerwinkle E. dbNSFP: a lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011; 32(8): 894–9.
Codina-Sola M., Rodriguez-Santiago B., Homs A. Integrated analysis of whole-exome sequencing and transcriptome profiling in males with autism spectrum disorders. Molecular
Autism. 2015; 6:21.
Robinson J. T., Thorvaldsdottir H., Winckler W. Integrative genomics viewer. Nature Biotechnology. 2011; 29(1): 24–6.
Da Huang W., Sherman B. T., & Lempicki R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols. 2011; 4(1):44–57.
Iourov I. Y., Vorsanova S. G., & Yurov Y. B. In silico molecular cytogenetics: a bioinformatic approach to prioritization of candidate genes and copy number variations for basic and clinical genome research. Molecular Cytogenetics. 2014; 7(1):98.
Meisner L. F., & Johnson J. A. Protocols for cytogenetic studies of human embryonic stem cells. Methods. 2008;45(2): 133–41.
O'hara D. M., Xu Y., Liang Z. Recommendations for the validation of flow cytometric testing during drug development: II assays. Journal of Immunological Methods. 2011; 363(2): 120–34.
Shi G., & Jin Y. Role of Oct4 in maintaining and regaining stem cell pluripotency. Stem Cell Research & Therapy. 2010; 1(5): 39.
Chou B. K., Mali P., Huang X. Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Research. 2011; 21(3):518–29.
Pease S., Braghetta P., Gearing D. Isolation of embryonic stem (ES) cells in media supplemented with recombinant leukaemia inhibitory factor (LIF). Developmental Biology. 1990; 141(2): 344–52.
Chin A. C., Padmanabhan J., Oh S. K. Defined and serum-free media support undifferentiated human embryonic stem cell growth. Stem Cells and Development. 2010; 19(6):753–61.
Goh P. A., Caxaria S., Casper C. A systematic evaluation of integration free reprogramming methods for deriving clinically relevant patient specific induced pluripotent stem (iPS) cells. PloS One. 2013; 8(11): 81622.
Mm B. An introduction to microarray data analysis. In: P. R, editor. In Computational genomics: Theory and application. United Kingdom.2004; 66: 225–49.
Muller F. J., Schuldt B. M., Williams R. A bioinformatic assay for pluripotency in human cells. Nature Methods. 2011; 8(4): 315–7.